Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen N Moore

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 12, 2019
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancerKathleen N Moore, Sandro Pignata,
Cancer Journal (Sudbury, Mass.)|December 14, 2021
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive ReviewKathleen N Moore, Bhavana Pothuri
The Oncologist|March 30, 2018
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and ExpectationsKathleen N Moore, Michael J Birrer
Expert Review of Anticancer Therapy|June 19, 2018
Niraparib for the treatment of ovarian cancerKathleen G Essel, Kathleen N Moore
The Oncologist|June 4, 2016
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian CancerKathleen N Moore, Bradley J Monk
Current Opinion in Obstetrics & Gynecology|December 28, 2020
PARP inhibitors in the treatment of ovarian cancer: a reviewChristina R Washington, Kathleen N Moore
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancerKathleen N Moore, Joan L Walker
Gynecologic Oncology|November 21, 2015
Is the NCI MATCH trial a match for gynecologic oncology?Kathleen N Moore, Robert S Mannel
Clinical Obstetrics and Gynecology|April 22, 2011
Uterine papillary serous carcinomaKathleen N Moore, Amanda Nickles Fader
Expert Review of Molecular Diagnostics|August 22, 2015
BRACAnalysis CDx as a companion diagnostic tool for LynparzaCamille C Gunderson, Kathleen N Moore
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 12, 2019
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancerKathleen N Moore, Sandro Pignata,
Cancer Journal (Sudbury, Mass.)|December 14, 2021
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive ReviewKathleen N Moore, Bhavana Pothuri
The Oncologist|March 30, 2018
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and ExpectationsKathleen N Moore, Michael J Birrer
Expert Review of Anticancer Therapy|June 19, 2018
Niraparib for the treatment of ovarian cancerKathleen G Essel, Kathleen N Moore
The Oncologist|June 4, 2016
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian CancerKathleen N Moore, Bradley J Monk
Current Opinion in Obstetrics & Gynecology|December 28, 2020
PARP inhibitors in the treatment of ovarian cancer: a reviewChristina R Washington, Kathleen N Moore
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancerKathleen N Moore, Joan L Walker
Gynecologic Oncology|November 21, 2015
Is the NCI MATCH trial a match for gynecologic oncology?Kathleen N Moore, Robert S Mannel
Clinical Obstetrics and Gynecology|April 22, 2011
Uterine papillary serous carcinomaKathleen N Moore, Amanda Nickles Fader
Expert Review of Molecular Diagnostics|August 22, 2015
BRACAnalysis CDx as a companion diagnostic tool for LynparzaCamille C Gunderson, Kathleen N Moore
Pageof 21